Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus
about
Obstructing toxin pathways by targeted pore blockageRecent progress in structure-based anti-influenza drug designM2 protein from influenza A: from multiple structures to biophysical and functional insightsInhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomersStructure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virusNew small-molecule drug design strategies for fighting resistant influenza ATwo birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicineAn assay suitable for high throughput screening of anti-influenza drugsInhibitors of the influenza A virus M2 proton channel discovered using a high-throughput yeast growth restoration assayFlipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel.Paramagnetic Cu(II) for probing membrane protein structure and function: inhibition mechanism of the influenza M2 proton channel.Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.Influenza virus m2 ion channel protein is necessary for filamentous virion formation.Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza ACoexistence of two adamantane binding sites in the influenza A M2 ion channel.Proton and cation transport activity of the M2 proton channel from influenza A virus.An efficient, optimized synthesis of fentanyl and related analogs.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesNew treatments for influenzaFunctional reconstitution of influenza A M2(22-62).Human monoclonal ScFv that bind to different functional domains of M2 and inhibit H5N1 influenza virus replication.Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors.Viral miniproteinsSolid-supported membrane technology for the investigation of the influenza A virus M2 channel activityBakuchiol Is a Phenolic Isoprenoid with Novel Enantiomer-selective Anti-influenza A Virus Activity Involving Nrf2 Activation.Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.Transmembrane communication: general principles and lessons from the structure and function of the M2 proton channel, K⁺ channels, and integrin receptors.Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus.Antiviral strategies against influenza virus: towards new therapeutic approaches.Exploring organosilane amines as potent inhibitors and structural probes of influenza a virus M2 proton channel.Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.Mechanisms of Action of Novel Influenza A/M2 Viroporin Inhibitors Derived from Hexamethylene Amiloride.Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited.Development and identification of a new Vero cell-based live attenuated influenza B vaccine by a modified classical reassortment method.Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses.Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction.An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers.
P2860
Q26827489-7AD8F3A4-3717-45FE-83F0-04BE9B1764E2Q26863710-2ED175F0-0295-4BC5-94DD-4CC83AD79D23Q26991579-69FA208C-E4CA-4D51-8ED0-91211DCD4585Q27673286-C9CA92A3-780F-495B-8DD2-8C619739A311Q27675846-B6046703-363D-4D82-9273-144293EF8EFBQ28080554-5C302460-E194-4393-A48E-3B798299E2A3Q28478569-63E36FD9-050A-4EA6-B5C6-37A6862491A9Q28484953-BF1A5EB6-F4A9-4316-BB33-17E2610C6969Q28485914-F663E0EC-F3E7-4684-AA82-F7B4EB41BC5CQ30369353-44DF74EB-E99D-459A-9268-4CFCA361B4DDQ30415676-11DFA2F2-3B18-49CC-9C6B-95C3E185352EQ30427556-309971F1-6267-479B-A313-98E7183294ECQ33826913-5321634B-AC99-4972-B701-3376692FDBEAQ34023430-D7D87C0D-6BCA-42F0-968F-EC26288B19CCQ34068392-F81AE57A-DBF1-4B63-881E-7DCAA6220B64Q34100507-A270E49E-59CE-4A8B-AC98-B7AE222B909FQ34215292-EC16A744-E5C3-4613-83C0-FF8D96062F15Q34329204-2372BDEF-945C-4721-8AB7-8BBB00135834Q34413797-87F1D04B-A8F0-4203-81DE-2CA77D065679Q34420205-045967C8-A947-45FE-96AD-79B678F2F3F2Q34721639-25C4BA01-A1C0-4B90-93F3-445C3C1D5F74Q34864675-8DE81D12-1F3A-4FE8-AAFE-4D4416747FCDQ35151120-7A2B8CFE-2559-4F00-B4B3-0CE5AA6F95CCQ36193000-EC255C66-F3C9-4E3A-B11A-A20FFF4B889BQ36282965-AA234726-03FE-4032-9617-E3A781BD2A1CQ36791678-15B67187-73CE-465D-95C4-7061993FDACBQ37156475-51970CAB-D3AC-4CE4-B60E-8FC6B1E9210DQ37830140-1B3BCCF3-64E0-4F61-8BBA-6B8595EFB046Q38202012-0476B081-55DD-473E-AB74-F8DB92DCBF33Q38291733-26F79088-DA50-4C2D-B351-F8106FA2EA1FQ38452544-A5742E7D-C926-47A4-98C1-7EDBDAE4147BQ38770144-6120BC19-5C6D-401B-8B13-644C9550600CQ38952446-FBA5EF72-D56A-4868-A0C7-D7B0E9879331Q40172861-7F5B4A97-200F-419D-BCAE-EAA29781B7A6Q40231604-2F9E7EAD-58FA-4E82-9F82-CB29DE288342Q40238930-28D38070-229D-48BD-B48E-87B769C2BFF2Q40338821-C38C2BB3-0558-4180-B04C-A846B32F196AQ40372317-7E305E5E-2397-41FA-B035-1F5B31EF50F2Q40531013-4707FC78-D0BF-4AC9-BC79-337CAD493B8DQ40622883-761A69F3-C671-4AE0-89FC-7EFC73AA439F
P2860
Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Design and pharmacological cha ...... n channel of influenza A virus
@en
Design and pharmacological cha ...... channel of influenza A virus.
@nl
type
label
Design and pharmacological cha ...... n channel of influenza A virus
@en
Design and pharmacological cha ...... channel of influenza A virus.
@nl
prefLabel
Design and pharmacological cha ...... n channel of influenza A virus
@en
Design and pharmacological cha ...... channel of influenza A virus.
@nl
P2093
P2860
P356
P1433
P1476
Design and pharmacological cha ...... n channel of influenza A virus
@en
P2093
Emma Magavern
Lawrence H Pinto
Robert A Lamb
Victoria Balannik
William F Degrado
Xianghong Jing
Yuki Ohigashi
P2860
P304
11872-11882
P356
10.1021/BI9014488
P407
P50
P577
2009-12-01T00:00:00Z